Targeted Treatment of Acute Myeloid Leukemia Based on Epigenetic Regulation Mechanism
DOI:
https://doi.org/10.61173/6yecxn21Keywords:
Cancer, leukemia, epigeneticsAbstract
Acute myeloid leukemia (AML) is a kind of malignant clone system disease of hematopoietic ancestor cells. Objects genetic modification plays an important role in the occurrence and development of AML. The current research shows that apparently, genetic modifications, such as DNA methylation, group protein modification, non-encoding RNA-mediated regulation, etc., play a key role in AML and become potential treatment targets. However, there are still research gaps in the targeted therapy for AML epigenetics, and further exploration and research need to be done. This article summarizes the epigenetic pathogenesis and types of AML and analyzes targeted therapeutic strategies for AML epigenetic modification, including DNA methyl metastase inhibitors, histone deaminase inhibitors, and non-encoding RNA. The results showed that these strategies showed potential treatment effects in preclinical and clinical studies and provided new ideas for AML treatment. The significance of this summary is to provide a reference for future AML therapy research, which indicates the importance of apparent genetic modification in AML treatment. However, there are still many problems that need to be solved, including the durability, drug resistance, and side effects of treatment. Future research can focus on these issues so as to bring more effective treatment plans to patients with AML.
References
[1] Döhner, H., Estey, E. H., Grimwade, D., et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2017, 129(4), 424– 447.
[2] Man, C. H., Fung, T. K., Wan, H., et al. Suppression of SOX7 by DNA methylation and its tumor suppressor function in acute myeloid leukemia. Blood, 2015, 125(25), 3928–3936. Ma Kunlong. Short term distributed load forecasting method based on big data. Changsha: Hunan University, 2014.
[3] Azadniv, M., Myers, J. R., McMurray, et al. Bone marrow mesenchymal stromal cells from acute myelogenous leukemia patients demonstrate adipogenic differentiation propensity with implications for leukemia cell support. Leukemia, 2019, 34(2), 391–403.
[4] Ley, T. J., Li, D., Walter, M. J., et al. DNMT3AMutations in acute myeloid leukemia. The New England Journal of Medicine, 2010, 363(25), 2424–2433.
[5] Molenaar, R. J., Radivoyevitch, T., Nagata, Y., et al. IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-Mutant inhibitors. Clinical Cancer Research, 2018, 24(7), 1705–1715.F
[6] Dhall, A., Zee, B. M., Yan, F., & Blanco, M. A. Intersection of epigenetic and metabolic regulation of Histone modifications in acute myeloid leukemia. Frontiers in Oncology, 2019, 9.
[7] Luan, C., Yang, Z., & Chen, B. The functional role of microRNA in acute lymphoblastic leukemia: relevance for diagnosis, differential diagnosis, prognosis, and therapy. OncoTargets and Therapy,2015, 2903.
[8] Gerloff, D., Grundler, R., Wurm, A., et al. NF-κB/STAT5/ miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia, 2014, 29(3), 535–547.
[9] Zimta, A., Tomuleasa, C., Sahnoune, I., & Calin, G. A. Long noncoding RNAs in myeloid malignancies. Frontiers in Oncology, 2019, 9.
[10] Singh, V. K., Uddin, M. H., Zonder, J. A., et al. Circular Dean&Francis RNAs in acute myeloid leukemia. Molecular Cancer, 2021, 20(1).
[11] Xu, J., Song, F., Lyu, H., et al. Subtype-specific 3D genome alteration in acute myeloid leukaemia. Nature, 2022c, 611(7935), 387–398.
[12] Pappalardi, M. B., Keenan, K., Cockerill, M., et al. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nature Cancer, 2021, 2(10), 1002–1017.
[13] Shanqi Guo, Yizhuo Zhang. ().Histone Deacetylase Inhibition: An Important Mechanism in the Treatment of Lymphoma. Cancer Biol Med. 2012 Jun; 9(2): 85–89.
[14] Van Veggel, M., Westerman, E. M., & Hamberg, P. Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat. Clinical Pharmacokinectics, 2017, 57(1), 21–29.
[15] Savickienė, J., Treigytė, G., Valiulienė, G., et al. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells. Anti-Cancer Drugs, 2014, 25(8), 938–949.
[16] Valiulienė, G., Stirblytė, I., Jasnauskaitė, M., et al. Antileukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells. European Journal of Pharmacology, 2017, 799, 143–153.
[17] Issa, H., Bhayadia, R., Winkler, R., et al. Preclinical testing of miRNA-193b-3p mimic in acute myeloid leukemias. Leukemia, 2023, 37(7), 1583–1587.
[18] Salemi, D., Cammarata, G., Agueli, C., et al. miR-155 regulative network in FLT3 mutated acute myeloid leukemia. Leukemia Research, 2015, 39(8), 883–896.
[19] Sheng, X., Hong, L., Li, H., et al. Long noncoding RNA MALAT1 modulate cell migration, proliferation and apoptosis by sponging microRNA-146a to regulate CXCR4 expression in acute myeloid leukemia. Hematology, 2020, 26(1), 43–52.
[20] Feng, Y., Hu, S., Li, L., Zhang, S., et al. LNCRNA NR- 104098 inhibits AML proliferation and induces differentiation through repressing EZH2 transcription by interacting with E2F1. Frontiers in Cell and Developmental Biology, 2020, 8.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
